StockData
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. (SABSW) stock

SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 4/30
$0.01+0.00 (+33.33%)

Close on Oct 20, 2026Market cap $304.80MP/E –Yield –

Earnings

SAB Biotherapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of SAB Biotherapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2023ended Dec 31, 2023Mar 29, 2024during market hours–––Release
Q4 FY2022ended Dec 31, 2022Mar 31, 2023after the close–––Release
Q3 FY2021ended Sep 30, 2021Nov 22, 2021before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

SAB Biotherapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When SAB Biotherapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases SAB Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
    News
  2. Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
    Update
  3. SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
    Update
  4. 8-K exhibit EX-99.2
    Update
  5. SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    News
  6. SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock
    News
  7. SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
    Update
  8. Corporate Presentation Q1 2026 Targeting T1D Modifying Disease Moving Beyond Insulin EXHIBIT 99.2
    Update
  9. Corporate Presentation January 2026 Modifying Disease Delaying Progression Transforming Treatment Company Logo © 2026 SAB BIOTHERAPEUTICS, INC. Exhibit 99.1
    Update
  10. SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
    Update
  11. SAB BIO Announces Oversubscribed $175 Million Private Placement
    News
  12. SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
    News
  13. SAB BIO INNOVATION DAY ACCELERATING DISEASE-MODIFYING TREATMENTS IN AUTOIMMUNITY January 28, 2025 (Nasdaq: SABS) EXHIBIT 99.2
    News
  14. SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
    Update
  15. SAB Biotherapeutics European Association for the Study of Diabetes 60th Annual Meeting INNODIA SYMPOSIUM Madrid, Spain September 9, 2024 © 2024 SAB BIOTHERAPEUTICS, INC. EXHIBIT 99.2
    Update